ライフサイエンスコーパス: GMP

1 GMP, common in many human cancers but of uncertain origi

2 GMP-MFs provide a safe and acceptable option for the nut

3 GMPs and MDPs were also independently mobilized to produ

4 GMPs and MDPs yielded classical (Ly6C(hi)) monocytes wit

5 GMPs produced a subset of "neutrophil-like" monocytes, w

6 ction of several dietary 5'-NMPs, such as 5'-GMP and 5'-IMP, was carried out at high concentrations o

7 influences steady-state concentrations of 5'-GMP, ribose-5-phosphate, ketone bodies, and purines.

8 bone marrow, as well as lineage choice after GMP, promoting increased neutrophil output at the expens

9 a decrease in granulocyte progenitors among GMP cells.

10 the asymmetric signaling molecule cyclic AMP-GMP (cAG or 3', 3'-cGAMP).

11 oliferation and increased numbers of LSK and GMP cells compared with WT mice.

12 At the steady state, BCAP(-/-) GMP cells expressed more IRF8 and less C/EBPalpha than d

13 (CMPs), and a hierarchical relationship (CMP-GMP-MDP-monocyte) is presumed to underlie monocyte diffe

14 As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical

15 Cyclic GMP (cGMP) generated in the granulosa cells diffuses thr

16 Cyclic GMP-AMP (cGAMP) synthase (cGAS) is a cytosolic DNA senso

17 Cyclic GMP-AMP synthase (cGAS) is an essential DNA virus sensor

18 Cyclic GMP-AMP synthase is essential for innate immunity agains

19 Cyclic GMP-AMP synthetase (cGAS) is a DNA-specific cytosolic se

20 uired for the inhibition of the 2',3'-cyclic GMP-AMP (cGAMP)-dependent immune responses during infect

21 Wang et al. now report on a cyclic GMP-AMP adjuvant, the natural stimulator of interferon g

22 ous DNA substrate of TREX1 triggers a cyclic GMP-AMP synthase-dependent type I IFN response and syste

23 f human monocytes binds and activates cyclic GMP-AMP synthase (cGAS).

24 LR9) in the endosomal compartment and cyclic GMP-AMP synthase (cGAS) and absent in melanoma 2 (AIM2)

25 ionally, we determined that STING and cyclic GMP-AMP synthase (cGAS) are important to engage the type

26 ampus that breaks down cyclic AMP and cyclic GMP.

27 autoimmune therapies.Upon DNA binding cyclic GMP-AMP synthase (cGAS) produces a cyclic dinucleotide,

28 Upon binding double-stranded DNA, cyclic GMP-AMP synthase synthesizes a cyclic dinucleotide that

29 PRKG1 encodes cyclic GMP-dependent protein kinase 1, which is involved in lea

30 Endogenous cyclic GMP-AMP (cGAMP) binds and activates STING to induce type

31 s targeting the Plasmodium falciparum cyclic GMP-dependent protein kinase (PfPKG).

32 ow here that K-Ras is a substrate for cyclic GMP-dependent protein kinases (PKGs).

33 plifier that operates downstream from cyclic GMP-gated cation channels and distal guanylate cyclases.

34 ave compared the dependency on IFI16, cyclic GMP-AMP synthase, and stimulator of IFN genes for type I

35 Mice genetically deficient in cyclic GMP-AMP synthase (cGAS), its adaptor STING, IRF3, or the

36 for ETEC-induced diarrhea, including cyclic GMP (cGMP) produced by GUCY2C, activation of cGMP-depend

37 ith DMXAA or the natural STING ligand cyclic GMP-AMP (cGAMP).

38 Thus FGF signaling lowers cyclic GMP production in the growth plate, which counteracts bo

39 an in vivo imaging system to measure cyclic GMP production in intact tibia, we show that FGF-induced

40 , which produces the second messenger cyclic GMP-AMP (cGAMP).

41 phosphorylated and thus produces more cyclic GMP.

42 s and cytokines through activation of cyclic GMP-AMP synthase (cGAS) and stimulator of interferon gen

43 understanding the biological roles of cyclic GMP-AMP synthase and can serve as a molecular scaffold f

44 we report the discovery of a class of cyclic GMP-AMP synthase inhibitors identified by a high-through

45 and we present crystal structures of cyclic GMP-AMP synthase, double-stranded DNA, and inhibitors wi

46 e and selective in cellular assays of cyclic GMP-AMP synthase-mediated signaling and reduces constitu

47 nalyses showed enhanced generation of cyclic GMP-AMP, STING aggregation, and TANK-binding kinase 1 an

48 w expression of the antiviral protein cyclic GMP-AMP synthase (cGAS) in neuronal SH-SY5Y cells, which

49 ion though the cytosolic DNA receptor cyclic GMP-AMP synthase (cGAS), which produces the second messe

50 for the pattern-recognition receptor cyclic GMP-AMP synthase (cGAS).

51 One of several upstream receptors, cyclic GMP-AMP synthase, binds to cytosolic DNA and generates d

52 in mice) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-beta produc

53 te the stable assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme.

54 tease cofactor targets the DNA sensor cyclic GMP-AMP synthase (cGAS) for lysosomal degradation to avo

55 the roles of the putative DNA sensor cyclic GMP-AMP synthase (cGas), as well as the downstream IFN r

56 he double-stranded DNA (dsDNA) sensor cyclic GMP-AMP synthase (cGAS), the innate immune adaptor STING

57 ivation of the cytoplasmic DNA sensor cyclic GMP-AMP synthase by a nucleic acid substrate of Trex1 th

58 lar sensors including the DNA sensors cyclic GMP-AMP (cGAMP) synthase (cGAS) and interferon gamma (IF

59 ity cytosolic DNA-sensing cGAS-STING (cyclic GMP-AMP synthase linked to stimulator of interferon gene

60 is sensing mechanism by targeting the cyclic GMP-AMP synthase (cGAS) and the stimulator of interferon

61 yndrome demonstrate that ablating the cyclic GMP-AMP synthase gene abolishes the deleterious phenotyp

62 etic silencing of either STING or the cyclic GMP-AMP synthase, which generates STING-activating cycli

63 cal DNA sensor proposed to act in the cyclic GMP-AMP synthase-stimulator of IFN genes pathway.

64 largely by chronic activation of the cyclic GMP-AMP synthase-stimulator of interferon genes-TANK-bin

65 o prevent autoimmunity; despite this, cyclic GMP-AMP synthase (cGAS), a cytosolic sensor of double-st

66 to human CMV that are dependent upon cyclic GMP-AMP synthase (cGAS), STING, and interferon regulator

67 Cyclic-GMP is a second messenger in phototransduction, a G-prot

68 mtDNA was recognized by cyclic-GMP-AMP synthase (cGAS) in the DC cytosol, contributing

69 bserve expanding GMP patches forming defined GMP clusters, which, in turn, locally differentiate into

70 , the intracellular secondary messenger c-di-GMP (Bis-(3'-5')-cyclic dimeric guanosine monophosphate)

71 The second messenger c-di-GMP (or cyclic diguanylate) regulates biofilm formation,

72 ein MapZ cocrystallized in complex with c-di-GMP and its protein target CheR1, a chemotaxis-regulatin

73 incidence detection that relies on both c-di-GMP and LapG binding to LapD for receptor activation.

74 he in situ, real time quantification of c-di-GMP and show that the amount of this biofilm-regulating

75 activity such that the protein degrades c-di-GMP and thereby inhibits matrix production during oxidiz

76 As high levels of c-di-GMP are associated with the biofilm lifestyle, c-di-GMP

77 methodologies for the quantification of c-di-GMP are typically based on chemical extraction, represen

78 ovirus vaccine, fostering production of c-di-GMP as well as proinflammatory responses in mice.

79 5) from Vibrio cholerae in complex with c-di-GMP at a 1.37 A resolution.

80 hly conserved residues markedly reduces c-di-GMP binding and biofilm formation by V. cholerae.

81 ough unrelated in sequence, the mode of c-di-GMP binding to CuxR is highly reminiscent to that of Pil

82 nsights into the molecular evolution of c-di-GMP binding to proteins.

83 coupling of the ATPase active site and c-di-GMP binding, as well as the functional significance of c

84 conserved motifs with high affinity for c-di-GMP binding, the findings here suggest that c-di-GMP can

85 Here, we show that c-di-GMP binds BldD using an ordered, sequential mechanism an

86 luding a large set of genes involved in c-di-GMP biosynthesis, degradation, and transmission.

87 In addition, a CfcR-dependent c-di-GMP boost was observed during this stage in DeltarsmIEA

88 In their c-di-GMP bound conformation Cle proteins interact with the fl

89 c-di-GMP can assume alternative oligomeric states to effect d

90 binding, the findings here suggest that c-di-GMP can regulate both motility and biofilm formation thr

91 c-di-GMP caused a persistent increase in cAMP, which still oc

92 Indeed, domain reorientation by c-di-GMP complexation with MrkH, which leads to a highly comp

93 e biofilm and thus represent an average c-di-GMP concentration across the entire biofilm.

94 BldD activity is controlled by c-di-GMP concentration and BldO potentially responds to an un

95 uorescence was calibrated against known c-di-GMP concentrations.

96 e detailed structural insights into how c-di-GMP controls the activity of an enzyme target indirectly

97 ponse regulator domain that resulted in c-di-GMP degradation.

98 t is induced by binding an intercalated c-di-GMP dimer.

99 osphodiesterase mutant producing excess c-di-GMP displays marked attenuation in vitro and in vivo dur

100 ich is responsible for most of the free c-di-GMP during stationary phase in static conditions.

101 sing inhibition of protease LapG by the c-di-GMP effector protein LapD, and resulting in proteolysis

102 than did wild-type Brucella or the low-c-di-GMP guanylate cyclase DeltacgsB mutant.

103 associated with the biofilm lifestyle, c-di-GMP hydrolysing phosphodiesterases (PDEs) have been iden

104 biofilms, nutrient starvation triggers c-di-GMP hydrolysis by phosphodiesterase BifA, releasing inhi

105 , our results indicate a vital role for c-di-GMP in allowing Brucella to successfully navigate stress

106 This is an additional role for c-di-GMP in bacterial physiology.

107 To determine the role of c-di-GMP in Brucella physiology and in shaping host-Brucella

108 m Azoarcus sp. strain CIB that degrades c-di-GMP in response to aromatic hydrocarbons, including tolu

109 that cAMP is also the intermediate for c-di-GMP in vivo.

110 ree CheR1, revealed that the binding of c-di-GMP induces dramatic structural changes in MapZ that are

111 estinal pathogen Clostridium difficile, c-di-GMP inhibits flagellar motility and toxin production and

112 ions in apo structure stabilization and c-di-GMP interaction allows distinction between the states.

113 c-di-GMP interaction leads to active site obstruction, hexame

114 c-di-GMP interacts with a conserved N-terminal RxxxR motif an

115 c-di-GMP interacts with PilZ C-domain motifs 1 and 2 (RxxxR a

116 C-di-GMP is a bacterial second messenger regulating various c

117 owever, at physiological concentrations c-di-GMP is a monomer and little is known about how higher ol

118 Although c-di-GMP is known to stimulate the innate sensor STING, surpr

119 RsmA also showed a negative impact on c-di-GMP levels in a double mutant DeltarsmIE through the con

120 ld-the input stimuli-into intracellular c-di-GMP levels that then regulate genes for biofilm formatio

121 cally regulated by GTP, further linking c-di-GMP levels to nutrient availability.

122 restoring BrlR production and cellular c-di-GMP levels to wild-type levels.

123 Global c-di-GMP levels were unaffected by spermine supplementation,

124 S biosynthesis gene cluster at elevated c-di-GMP levels.

125 DE, PdcA, 1 of 37 confirmed or putative c-di-GMP metabolism proteins in C. difficile 630.

126 V/I)xxxxLxxxLxxQ that binds half of the c-di-GMP molecule, primarily through hydrophobic interactions

127 The c-di-GMP network has a bow-tie shaped architecture that integ

128 propose a mathematical model where the c-di-GMP network is analogous to a machine learning classifie

129 daptation though incremental changes in c-di-GMP network proteins acquires knowledge from past experi

130 the elusive function of the ubiquitous c-di-GMP network, a key regulator of bacterial social traits

131 c-di-GMP often regulates the function of its protein targets

132 ew provides an up-to-date compendium of c-di-GMP pathways connected to biofilm formation, biofilm-ass

133 l and biochemical characterization of a c-di-GMP PDE, PdcA, 1 of 37 confirmed or putative c-di-GMP me

134 , the CFP/GFP ratio gives the effective c-di-GMP per biomass.

135 onse regulator domain, and a C-terminal c-di-GMP phosphodiesterase (PDE) domain.

136 variations in local rather than global c-di-GMP pools.

137 ct DGC activity of SadC, OdaI inhibited c-di-GMP production by SadC.

138 a-barrel domain, represents a prototype c-di-GMP receptor.

139 GMP-metabolizing enzymes but lack known c-di-GMP receptors.

140 data that reveal an unexpected mode of c-di-GMP recognition that is associated with major conformati

141 Proteomics analysis revealed that c-di-GMP regulates several processes critical for virulence,

142 host-Brucella interactions, we utilized c-di-GMP regulatory enzyme deletion mutants.

143 as a biomass indicator and the GFP as a c-di-GMP reporter.

144 MP, whereas PKA activation bypassed the c-di-GMP requirement for stalk gene expression.

145 Using flow cells for biofilm formation, c-di-GMP showed a non-uniform distribution across the biofilm

146 and used these genes to investigate the c-di-GMP signal transduction pathway.

147 nce factors, and suggest a link between c-di-GMP signaling and nutrient availability.

148 ated, but the specific cues that impact c-di-GMP signaling are largely unknown.

149 A main effector for c-di-GMP signaling in the opportunistic pathogen Pseudomonas

150 the proposed global and local models of c-di-GMP signaling specificity in bacteria, and attempts to i

151 (c-di-GMP), by increased activity of a c-di-GMP specific phosphodiesterase.

152 data confirm that in vivo synthesis of c-di-GMP stimulates strong innate immune responses that corre

153 been ascribed to any of the individual c-di-GMP synthases or phosphodiesterases (PDEs).

154 he complex metabolic pathways governing c-di-GMP synthesis and degradation are highly regulated, but

155 st that the regulation of chemotaxis by c-di-GMP through MapZ orthologs/homologs is widespread in pro

156 onse to binding of the second messenger c-di-GMP to a C-terminal extension.

157 Additionally, c-di-GMP was found to be localized at the outer boundary of m

158 The 3D structure of MotI bound to c-di-GMP was solved, and MotI-fluorescent fusions localized a

159 0848) that produces elevated amounts of c-di-GMP when expressed in mammalian cells in vivo.

160 cyclic-dimeric-guanosine monophosphate (c-di-GMP) acts as an innate immune system modulator.

161 Cyclic dimeric GMP (c-di-GMP) has emerged as a key regulatory player in the trans

162 cterial second messenger cyclic di-GMP (c-di-GMP) has emerged as a prominent mediator of bacterial ph

163 cyclic dimeric guanosine monophosphate (c-di-GMP) is a dynamic intracellular signaling molecule that

164 yclic di-3',5'-guanosine monophosphate (c-di-GMP) is a key regulator of bacterial motility and virule

165 Cyclic diguanylate (c-di-GMP) is a near universal signaling molecule produced by

166 Cyclic diguanosine monophosphate (c-di-GMP) is a second messenger that controls diverse functio

167 signaling molecule cyclic diguanylate (c-di-GMP) mediates physiological adaptation to extracellular

168 '-5') cyclic diguanosine monophosphate (c-di-GMP) phosphodiesterase MbaA.

169 The cyclic di-GMP (c-di-GMP) second messenger represents a signaling system that

170 BldD-(c-di-GMP) sits on top of the regulatory network that controls

171 aryotic second messenger cyclic di-GMP (c-di-GMP) to coordinate responses to shifting environments.

172 messenger, 3-5 cyclic diguanylic acid (c-di-GMP) to the master repressor, BldD.

173 f bis-(3',5')-cyclic-dimeric-guanosine (c-di-GMP), a second messenger that stimulates matrix producti

174 e second messenger, cyclic diguanylate (c-di-GMP), by increased activity of a c-di-GMP specific phosp

175 ously reported that cyclic diguanylate (c-di-GMP), synthesized by diguanylate cyclase A (DgcA), induc

176 ated by a 3',5'-cyclic diguanylic acid (c-di-GMP)-regulated transcription factor, MrkH.

177 cyclic dimeric guanosine monophosphate (c-di-GMP).

178 necessitates the assembly of the BldD2-(c-di-GMP)4 complex.

179 structures to identify target genes for c-di-GMP, and used these genes to investigate the c-di-GMP si

180 pendent host response to cytosolic DNA, c-di-GMP, cGAMP, HIV-1, and DNA viruses.

181 prototypical transmembrane receptor for c-di-GMP, LapD, and a cognate periplasmic protease, LapG.

182 k cells reduced stalk gene induction by c-di-GMP, whereas PKA activation bypassed the c-di-GMP requir

183 This structure reveals a unique c-di-GMP-binding mode, featuring a tandem array of two highly

184 xxR and D/NxSxxG) and a newly described c-di-GMP-binding motif in the MrkH N domain.

185 This c-di-GMP-binding motif is present in diverse bacterial protei

186 Strikingly, these c-di-GMP-binding motifs also stabilize an open state conforma

187 esidues in the C-domain motif 2 and the c-di-GMP-binding N-domain motif.

188 Comparison of apo- and c-di-GMP-bound MrkH structures reveals a large 138 degrees in

189 As revealed by the structure of c-di-GMP-complexed FleQ, the second messenger interacts with

190 E gene is sufficient to impact multiple c-di-GMP-dependent phenotypes, including the production of ma

191 al changes in the receptor that lead to c-di-GMP-dependent protease recruitment.

192 agenesis shows that M6 killing requires c-di-GMP-dependent signalling, diverse fungicides and resista

193 me without undesired cross talk between c-di-GMP-dependent systems.

194 MN) variant class, and also variants of c-di-GMP-I and -II riboswitches that might recognize differen

195 t the restrictive temperature prevented c-di-GMP-induced cAMP synthesis as well as c-di-GMP-induced s

196 i-GMP-induced cAMP synthesis as well as c-di-GMP-induced stalk gene transcription.

197 Many bacteria contain c-di-GMP-metabolizing enzymes but lack known c-di-GMP recepto

198 receptor function and may also apply to c-di-GMP-metabolizing enzymes that are akin to LapD.

199 protein (GFP) under the control of the c-di-GMP-responsive cdrA promoter (Rybtke, M.

200 protein (GFP) under the control of the c-di-GMP-responsive cdrA promoter.

201 We identified a class of c-di-GMP-responsive proteins, represented by the AraC-like tr

202 mechanism of a previously unrecognized c-di-GMP-responsive transcription factor and provide insights

203 work also revealed a basal affinity of c-di-GMP-unbound receptor for LapG, the relevance of which re

204 biofilm, with concentrated hot spots of c-di-GMP.

205 talyze the synthesis and degradation of c-di-GMP.

206 synthesis genes in response to cellular c-di-GMP.

207 d by the intracellular second-messenger c-di-GMP.

208 rmation were shown to specifically bind c-di-GMP.

209 itions by modulating cellular levels of c-di-GMP.

210 imming motility or global intracellular c-di-GMP.

211 ide (biofilm matrix component) and cyclic di-GMP (biofilm-regulatory molecule) were detected in 6/6 m

212 The bacterial second messenger cyclic di-GMP (c-di-GMP) has emerged as a prominent mediator of ba

213 The cyclic di-GMP (c-di-GMP) second messenger represents a signaling s

214 y the prokaryotic second messenger cyclic di-GMP (c-di-GMP) to coordinate responses to shifting envir

215 diguanylate cyclases that produce cyclic di-GMP (cdiG), a second messenger that modulates the key ba

216 sensing, two-component systems and cyclic di-GMP signalling.

217 ensors that respond selectively to cyclic di-GMP, an intracellular bacterial second messenger that co

218 Valentini and Filloux focus on cyclic di-GMP, while Kavanaugh and Horswill discuss the quorum-sen

219 intracellular levels of the signal cyclic-di-GMP increase upon surface adhesion and that this is requ

220 r)) system, as being important for cyclic-di-GMP production and for biofilm formation.

221 The universal cyclic-di-GMP second messenger is instrumental in the switch from

222 e feedback between mechanosensors, cyclic-di-GMP signaling, and production of adhesive polysaccharide

223 by the corresponding activation of cyclic-di-GMP signaling, can be adjusted both by varying the stren

224 for surface adhesion and activates cyclic-di-GMP signaling.

225 cally partitioned second messenger cyclic-di-GMP, inhibiting kinase activity while stimulating phosph

226 We established that WarA binds to cyclic-di-GMP, which potentiates its methyltransferase activity.

227 on of the intracellular messenger, cyclic-di-GMP.

228 Cyclic dimeric GMP (c-di-GMP) has emerged as a key regulatory player in

229 distinct interactions in E.IMP.NADP(+) and E.GMP.NADP(+) complexes.

230 motion of the cofactor is enhanced in the E.GMP.NADP(+) complex.

231 During regeneration, we observe expanding GMP patches forming defined GMP clusters, which, in turn

232 (AA-MFs) or glycomacropeptide medical foods (GMP-MFs) that contain primarily intact protein and a sma

233 has been designed to meet specifications for GMP production, required for manufacture of advanced the

234 G-quartets form by the self-assembly of four GMP nucleotides.

235 te a significant increase in Phe intake from GMP-MFs (88 +/- 6 mg Phe/d, P = 0.026).

236 Herein, we identified GMP synthetase (GMPS), a key enzyme of de novo purine bi

237 MP was beneath the threshold of detection in GMP or MEP.

238 In the steady state, we find individual GMPs scattered throughout the bone marrow.

239 ntly different (AA-MFs = 444 +/- 34 mumol/L, GMP-MFs = 497 +/- 34 mumol/L), suggesting similar Phe co

240 te-macrophage progenitors (GMP) and leukemic GMP.

241 ineage progenitors were present among LMPPs, GMPs and MLPs.

242 dently optimizing and robustly manufacturing GMP compliant precision particles of virtually any size,

243 ne (N-Ac-Tyr) or guanosine-5'-monophosphate (GMP) was investigated at various pH values.

244 In dilute 5'-guanosine monophosphate (GMP) solutions, G-quartets form by the self-assembly of

245 y disodium guanosine 5'-monophosphate (Na25'-GMP).

246 r are reached, the self-association of Na25'-GMP is most favoured.

247 allenge, we have characterized C. neoformans GMP synthase, the second enzyme in the guanylate branch

248 We show that in the absence of GMP synthase, C. neoformans becomes a guanine auxotroph,

249 Thus, the balance of GMP and MDP differentiation shapes the myeloid cell repe

250 ternary structure, induced by the binding of GMP, GTP, or ATP to the GMPR CBS domain.

251 ict NADPH-dependent reductive deamination of GMP to produce IMP.

252 ademic counterparts to meet higher levels of GMP compliance at earlier stages of clinical development

253 Addition of GTP or high levels of GMP induced a marked increase in activity without alteri

254 emperature as well as the pressure limits of GMP self-assembly.

255 relaxation profiles for the monophosphate of GMP compared with IMP in their respective NADP(+) comple

256 tical interactions for the monophosphates of GMP and IMP in several inert complexes.

257 ively, these data highlight the potential of GMP synthase to be exploited in the development of new t

258 reductase (GMPR) catalyzes the reduction of GMP to IMP and ammonia with concomitant oxidation of NAD

259 collapse to GMP, and subsequent reversion of GMP to normal microvessels, all without extensive vascul

260 previously unrecognized dynamic behaviour of GMPs in situ, which tunes emergency myelopoiesis and is

261 mouse MDPs arose from CMPs independently of GMPs, and that GMPs and MDPs produced monocytes via simi

262 STAG2 mutations can amplify at the level of GMPs, from which it may drive the transformation to acut

263 r usual low-Phe diet combined with AA-MFs or GMP-MFs.

264 we developed a good manufacturing practice (GMP) differentiation protocol for highly efficient and r

265 reservation and good manufacturing practice (GMP)-compatible culture, make this approach eminently su

266 ne developing, Good Manufacturing Practices (GMP) processes were surveyed as to their production meth

267 A good-manufacturing-practices (GMP) (68)Ge/(68)Ga generator that uses modified dodecyl-

268 ression and granulocyte monocyte precursors (GMPs), and protected from ameba infection.

269 F) signaling in SFB-colonized mice prevented GMP expansion, decreased gut neutrophils, and blocked pr

270 to track granulocyte/macrophage progenitor (GMP) behaviour in mice during emergency and leukaemic my

271 MEP), and granulocyte-macrophage progenitor (GMP) cells, accompanied by increased cell cycle arrest i

272 itor, and granulocyte/macrophage progenitor (GMP) cells.

273 ation of granulocyte-macrophage progenitors (GMP) and leukemic GMP.

274 nitors (CMPs), granulomonocytic progenitors (GMPs), and megakaryocytic-erythroid progenitors (MEPs).

275 (LMPPs), granulocyte-macrophage progenitors (GMPs) and multi-lymphoid progenitors (MLPs) - were funct

276 anism of granulocyte-macrophage progenitors (GMPs) employed in emergency hematopoiesis that is also h

277 Granulocyte-monocyte progenitors (GMPs) and monocyte-dendritic cell progenitors (MDPs) pro

278 rm glomeruloid microvascular proliferations (GMP), accompanied by only modest endothelial cell death.

279 Subjects rated GMP-MFs as more acceptable than AA-MFs and noted improve

280 trol the transient formation of regenerating GMP clusters.

281 ; the cofactor has faster local motions than GMP in the deamination complex but is more constrained t

282 In leukaemia, we show that GMP clusters are constantly produced owing to persistent

283 se from CMPs independently of GMPs, and that GMPs and MDPs produced monocytes via similar but distinc

284 The GMP-certified (68)Ge/(68)Ga generator system was studied

285 ecreased the GMPR activity and increased the GMP Km value 10-fold.

286 Using the GMP-quadruplex, built by the stacking of G-quartets with

287 termination of NUDT15 in complex with 6-thio-GMP.

288 ble catalysis of phosphotransfer from ATP to GMP.

289 NOS, causing vasocontraction, MV collapse to GMP, and subsequent reversion of GMP to normal microvess

290 We developed a method comparable to GMP quality protocols for deriving self-renewing perivas

291 i-VEGF/VEGFR drugs, rapidly collapsing MV to GMP.

292 Rv21 is progressing to GMP production and has entered a path towards clinical e

293 t Phl p 5.0109 PP5ar06007 was produced under GMP conditions and analyzed by an array of physicochemic

294 (68)Ga labeling of peptides using GMP kits was performed in 15-20 min, and the total produ

295 ound, Na2 [(HGMP)2 Mo5 O15 ]7 H2 O (1; where GMP=guanosine monophosphate), which spontaneously assemb

296 y and safety of a low-Phe diet combined with GMP-MFs or AA-MFs providing the same quantity of protein

297 uency of medical food intake was higher with GMP-MFs than with AA-MFs.

298 strointestinal symptoms and less hunger with GMP-MFs.

299 eptability and fewer side effects noted with GMP-MFs than with AA-MFs may enhance dietary adherence f

300 ed more IRF8 and less C/EBPalpha than did WT GMP cells, which correlated with an increase in monocyte